Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer

William W. Tseng, Adriana Deganutti, May N. Chen, Romaine E. Saxton, Carson D. Liu, G. Chandler, M. Jaffe, T. Brentnall, K. G. Billingsley

    Research output: Contribution to journalArticle

    52 Scopus citations

    Abstract

    Recent studies indicate that cyclooxygenase-2 (COX-2) is overexpressed in pancreatic adenocarcinoma and may play a critical role in this rapidly progressing form of cancer. A human pancreatic adenocarcinoma cell line, Mia PaCa-2, was incubated for 18 hours with 5 μmol/L of rofecoxib (Vioxx), a selective COX-2 inhibitor. Total RNA was isolated and gene expression analyzed by DNA microarray chips. In a separate experiment, athymic mice were orthotopically injected with 7.5 × 105 Mia PaCa-2 cells through a minilaparotomy. After 1 month, laparotomy was repeated to measure tumor size, and mice were randomized to receive reformulated rodent chow containing either 12.5 mg/kg/day of rofecoxib or no drug for 21 days. Tumor growth was assessed by comparing volume before and after treatment. In vitro, rofecoxib decreased gene expression of cyclin D1/PRAD1, a key component of cell cycle progression, while increasing expression of several cell cycle arrest genes, including p21/WAF1, p33/ING, GADD34, and GADD45 (P < 0.05). In vivo, tumor growth was significantly reduced in treated vs. control mice (P < 0.05). No systemic toxicity was observed in mice receiving rofecoxib. These data suggest that rofecoxib slows the growth of human pancreatic cancer through changes in gene expression that favor cell cycle arrest.

    Original languageEnglish (US)
    Pages (from-to)838-844
    Number of pages7
    JournalJournal of Gastrointestinal Surgery
    Volume6
    Issue number6
    DOIs
    StatePublished - Dec 1 2002

    Keywords

    • Cell cycle
    • Cyclooxygenase-2
    • Microarray
    • Pancreas cancer
    • Rofecoxib

    ASJC Scopus subject areas

    • Surgery
    • Gastroenterology

    Fingerprint Dive into the research topics of 'Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this